1. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. (October 2019) Authors: Baig, Hassam; Somlo, Barbara; Eisen, Melissa; Stryker, Scott; Bensink, Mark; Morrow, Phuong K Journal: Journal of oncology pharmacy practice Issue: Volume 25:Number 7(2019) Page Start: 1576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early use of erenumab in US real-world practice. (24th May 2021) Authors: Bogdanov, Alina; Chia, Victoria; Bensink, Mark; Urman, Robert; Fischer, Lauren; Rasmussen, Soeren; Szekely, Christine; Kallenbach, Lee Journal: Cephalalgia reports Issue: Volume 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Issue 4 (16th February 2021) Authors: Hines, Dionne M.; Shah, Shweta; Multani, Jasjit K.; Wade, Rolin L.; Buse, Dawn C.; Bensink, Mark Journal: Headache Issue: Volume 61:Issue 4(2021) Page Start: 590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. (3rd March 2020) Authors: Edelsberg, John; Weycker, Derek; Bensink, Mark; Bowers, Charles; Lyman, Gary H. Journal: Current medical research and opinion Issue: Volume 36:Number 3(2020) Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. Issue 2 (8th February 2022) Authors: Kawata, Ariane K.; Ladd, Mary Kate; Lipton, Richard B.; Buse, Dawn C.; Bensink, Mark; Shah, Shweta; Hareendran, Asha; Mannix, Sally; Mikol, Daniel Journal: Headache Issue: Volume 62:Issue 2(2022) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93. (3rd June 2018) Authors: Bensink, Mark; Edwards, Christine; Bowers, Charles; Campbell, Jon Journal: Journal of medical economics Issue: Volume 21:Number 6(2018) Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. (2nd December 2017) Authors: Weycker, Derek; Bensink, Mark; Lonshteyn, Alexander; Doroff, Robin; Chandler, David Journal: Current medical research and opinion Issue: Volume 33:Number 12(2017) Page Start: 2107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. (2nd December 2017) Authors: Weycker, Derek; Bensink, Mark; Wu, Hongsheng; Doroff, Robin; Chandler, David Journal: Current medical research and opinion Issue: Volume 33:Number 12(2017) Page Start: 2115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. (3rd April 2019) Authors: Weycker, Derek; Hanau, Ahuva; Lonshteyn, Alexander; Bowers, Charles; Garawin, Tamer; Bensink, Mark; Chandler, David Journal: Current medical research and opinion Issue: Volume 35:Number 4(2019) Page Start: 725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. (2nd September 2018) Authors: Weycker, Derek; Hanau, Ahuva; Lonshteyn, Alexander; Bowers, Charles; Bensink, Mark; Garawin, Tamer; Chandler, David Journal: Current medical research and opinion Issue: Volume 34:Number 9(2018) Page Start: 1705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗